24 Papers
31 Citations
Heran Li is an academic researcher from Shenyang Pharmaceutical University. The author has contributed to research in topics: Medicine & Mesoporous silica. The author has an hindex of 8, co-authored 14 publications.
Chat about Author
Papers
Chiral Nanosilica Drug Delivery Systems Stereoselectively Interacted with the Intestinal Mucosa to Improve the Oral Adsorption of Insoluble Drugs.
TL;DR: In this paper , mesoporous silica nanocarriers (l/d/dl-TA-PEI@CMSN) exhibiting the same structural parameters (hydrophilic, electroneutral, spherical NPs, ∼120 nm) but different geometrical chirality as oral nanodrug delivery systems (Nano-DDS) for insoluble drugs nimesulide (NMS) and ibuprofen (IBU) were designed.
24
Biomimetic synthesis and evaluation of histidine-derivative templated chiral mesoporous silica for improved oral delivery of the poorly water-soluble drug, nimodipine.
Heran Li,Haiting Li,Chen Wei,Jia Ke,Jing Li,Lu Xu,Hongzhuo Liu,YangYang,Sanming Li,Mingshi Yang,Mingshi Yang +10 more
TL;DR: In this study, spherical shaped chiral mesoporous silica nanoparticles (CMS) was biomimetic synthesized using histidine derivatives (C16‐L‐histidine) as template via the sol–gel reaction and employed as poorly water‐soluble drug nimodipine (NMP) carrier to improve the brain distribution of NMP in vivo.
23
Oral sustained-release suspension based on a novel taste-masked and mucoadhesive carrier–ion-exchange fiber
Jing Yuan,Tiaotiao Liu,Heran Li,Tianyu Shi,Jie Xu,Hongzhuo Liu,Zhiguo Wang,Qifang Wang,Lu Xu,Yan Wang,Sanming Li +10 more
TL;DR: In vitro results showed the releases of PF and coated PPN-fiber complexes (C-PF) were sustained, and a linear relationship between in vitro dissolution and in vivo absorption was observed.
23
Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis.
TL;DR: The preclinical pharmacokinetics of KBP-7018 in vitro and in vivo make it amenable to further oral solid dosage from design for the upcoming Phase I trials in human.
Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin.
TL;DR: It is believed that the effective delivery of IMC by Amino-CMSN will provide a new candidate to formulate poorly soluble drugs so as to significantly develop pharmaceutical application.
18